Australia's most trusted
source of pharma news
Thursday, 07 November 2024
Posted 17 July 2023 AM
Swedish rare immunological disease specialist Hansa Biopharma has not only registered its first drug in Australia but it has also received the broadest indication yet for the treatment.
The TGA has provisionally approved the company's lead product Idefirix as a desensitisation treatment for highly sensitised patients prior to kidney transplantation from a donor with whom there is a positive cross-match.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.